OSCR Sınıf A Oscar Health, Inc. Class A Common Stock
NYSE · Insurance · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 7, 2026OSCR Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
OSCR Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Oscar Health, Inc. Class A Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Oscar Management Corporation, doing business as Oscar Health is an American for-profit health insurance company, founded in 2012 by Joshua Kushner, Kevin Nazemi and Mario Schlosser, and is headquartered in New York City. The company sells health insurance and additionally provides other services in the health insurance industry through telemedicine, healthcare focused technological interfaces, and transparent claims pricing systems.
History
2012–2015
According to the company, it was founded in 2012 by Mario Schlosser, Joshua Kushner, and Kevin Nazemi, who were classmates at Harvard Business School. Mother Jones reported in March 2020 that Kushner and his brother, Jared, owned the firm's parent company, Thrive Partners III, at the time of its incorporation in 2013. Oscar began selling insurance for 2013, the same year that the Affordable Care Act exchanges and individual mandate went into effect for the 2014 plan year. In its first year, Oscar secured 16,000 members. In 2015, Oscar expanded coverage to New Jersey and grew to about 40,000 members.
2016
Oscar had 145,000 members in New York, New Jersey, California, and Texas in 2016. The firm expanded its operations to Tempe, Arizona, in August that year, where it decided to locate its Concierge teams, their name for their member services model. On August 23, Oscar announced it would be exiting the New Jersey Marketplace at the end of 2016, citing uncertainties in the market that would make it challenging "to operate effectively and continue to deliver access to quality healthcare." Oscar also announced that it would halve the size of its provider network in New York amidst rising premiums in order to "gain more control over pricing and patient experience".
In November 2016, the firm opened the Oscar Center in partnership with Mount Sinai Health System. Located in Brooklyn Heights, next to the Jay Street–MetroTech station, the Oscar Center had a primary care practice only available to Oscar policyholders, with a doctor, nurse practitioner, and a behavioral health specialist. It also hosted free classes for members, such as yoga classes or classes for expectant mothers. On March 13, 2020, Oscar closed the Oscar Center "until further notice."
2017
On April 25, 2017, Oscar announced its entrance into the small group insurance market, offering health plans in New York. On June 15, 2017, Oscar announced its partnership with Cleveland Clinic to offer individual health insurance plans to consumers in five counties in Northeastern Ohio.
On June 21, 2017, Oscar announced its intention to expand to additional markets in 2018 in areas of Tennessee, Ohio, Texas, New Jersey and California. On July 12, 2017, Oscar announced that it would be selling small group insurance in the Nashville metro area to companies with up to 50 employees through a strategic partnership with Humana.
A report by the New York Times in October 2017 speculated that Oscar Health had ties to Saudi Arabia. That month, Jared and Joshua Kushner visited Saudi Arabia's Crown Prince Mohammed bin Salman within days of each other. Despite Jared severing ties with Thrive Partners when he began working for the Trump administration, these coordinated visits raised questions about his ability to be impartial on Saudi affairs. Five months after Kushner's visit to Saudi Arabia in October 2017, Oscar Health announced a $165 million round of financing.
While a spokesman for Kushner said that Oscar Health's management didn't know of direct investment by the Saudis, he declined to disclose if Saudis had invested in Thrive funds. He only confirmed that Thrive hadn't received money from any Saudi parties since the presidential election. In May 2018, Jared Kushner disclosed $8.2 million in capital gains from Thrive funds.
2020–present
In January 2020, Oscar announced a partnership with Cigna to bring health insurance plans to small businesses. The partnership, Cigna + Oscar, will "launch in select markets in 2020 and plan to expand the partnership over time."
As of June 2020, Oscar had sold individual health insurance plans, both directly and through health insurance marketplaces, in New York, Texas and California. Oscar sells Medicare Advantage plans in New York City and Houston, Texas. Mario Schlosser is the company's CEO, after serving as Co-CEO with Nazemi until the latter's departure in early 2015. While Kushner does not hold a formal role in Oscar's daily operations, he remains a major shareholder and Schlosser confirmed (as of 2017) that he has "significant input in multiple aspects of the company like strategy, hiring, and marketing."
Oscar Health raised $1.2 billion on March 3, 2021, after an IPO.
Oscar Health reported 1.1 million members across its platform, which equates to 1 in 13 ACA exchange-based enrollees. The company announced it would exit the Arkansas and Colorado markets for plan year 2023.
Mario Schlosser steps down as CEO on April 3, 2023, transitioning to President of Technology. Mark Bertolini takes over as CEO.
In 2025, Oscar Health was ranked 437th by revenue on the Fortune 500 list and 42nd within the healthcare sector in the same rankings.
Marketing and brand
Oscar Health has run marketing campaigns on the New York City Subway. Bloomberg News reported the advertising campaigns feature cartoons suggesting "an easier way of getting medical care." AdWeek described Oscar Health's print ads as featuring "whimsical, animated characters".
In 2015, AdWeek reported that Oscar was airing its first television campaign targeted at the demographics of "new parents who are too frazzled to shop for health insurance." The ad launched on network stations in New Jersey and New York areas, cable, movie theaters located in New Jersey and in advertising within the Spotify app.
In 2016, Oscar ran a subway ad campaign with an educational bent around what the problems are with the American healthcare system.
Finances
Funding
Oscar has raised capital through a series of funding rounds. Its investors include Thrive Capital, General Catalyst Partners, Khosla Ventures, CapitalG, and Fidelity Investments.
During the May 2014 Series A round, Peter Thiel's Founders Fund led the series investing $30 million. By the close of Series A, Forbes reported the valuation of the company at $800 million.
During the 2015 Series B round, Oscar Health raised $145 million, bringing the total capital raised to $300 million, thus valuing the company at $1.5 billion. Series B investors included Formation 8, Horizons Ventures, Wellington Management Company, and Goldman Sachs.
In September 2015, Oscar announced a funding round with Google Ventures and Google Capital, valuing the company at $1.75 billion.
During the 2016 Series C round, Oscar raised $400 million led by Fidelity Investments, with secondary participation from previous investors, with a reported valuation of $2.7 billion. In 2018, Alphabet invested $375 million in Oscar Health. As of 2019, the company had raised $1.3 billion, and was valued at $3.2 billion.
In June 2020, Oscar raised $225 million in funding, in which the funding round saw participation from previous investors and also new investors, namely Baillie Gifford and Coatue.
Revenue
In 2014, New York magazine reported that as of May 2014, Oscar Health had 16,000 subscribers enrolled in its insurance program producing an estimated $72 million. In 2015, Forbes reported that Oscar Health had 40,000 subscribers with an average subscriber paying annual fees of $4,500, placing Oscar Health's revenue estimates at $180 million.
Vox reported that in 2015, Oscar Health lost $92.4 million in New York as the firm's analytical models failed to accurately forecast "the people who signed up for coverage were sicker than the company had expected."
By 2016, Oscar Health had 135,000 subscribers, with roughly half residing in New York State.
In February 2017, Bloomberg reported that Oscar had lost $204.9 million in 2016.
In May 2017, Bloomberg reported that Oscar's first quarter loss had narrowed by nearly half, writing that the company was "beginning to get a handle on its medical costs." In August 2017, Bloomberg also reported that Oscar had posted a $57.6 million loss in the first half of 2017, down from the $83 million lost posted the year prior.
In December 2017, TechCrunch reported that Oscar would expect to generate $1 billion in revenue and enroll 250,000 in 2018.
In January 2020, TechCrunch reported that Oscar served 400,000 members and expected to bring in $2 billion by the end of the year.
Headquarters and offices
Oscar's headquarters are located in Tribeca, New York City. They also have a technology outpost in Los Angeles and a member services operation in Tempe, Arizona.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | OSCR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 21.35Y ort. ≈23.0 | ≈23.0 | 15.4 | Aşırı değerli |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | OSCR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 4.1%5Y ort. ≈-9.1% | ≈-9.1% | 10.1% | Zayıf | |
| FAVÖK Marjı (TTM) | 4.3%5Y ort. ≈-8.6% | ≈-8.6% | 8.2% | Aynı seviyede | |
| Vergi Öncesi Kar Marjı (TTM) | 3.9%5Y ort. ≈-9.7% | ≈-9.7% | 17.3% | Zayıf | |
| Net Kâr Marjı (TTM) | 3.6%5Y ort. ≈-9.8% | ≈-9.8% | 10.3% | Zayıf | |
| ROA (TTM) | 6.3%5Y ort. ≈-8.6% | ≈-8.6% | 0.54% | Zayıf | |
| ROE (TTM) | 34.3%5Y ort. ≈-27.6% | ≈-27.6% | 12.2% | Zayıf | |
| ROIC | -28.5%5Y ort. ≈-21.5% | ≈-21.5% | 15.6% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | OSCR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.25Y ort. ≈0.3 | ≈0.3 | 0.0 | Yüksek borç | |
| Cari Oran (MRQ) | 1.15Y ort. ≈1.1 | ≈1.1 | · | · | |
| Quick Ratio (Cari Oran) | 0.65Y ort. ≈0.6 | ≈0.6 | · | · | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.25Y ort. ≈0.3 | ≈0.3 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | OSCR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 27.5%5Y ort. ≈109.0% | ≈109.0% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 43.5%5Y ort. ≈82.5% | ≈82.5% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 90.8% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | OSCR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 2.15Y ort. ≈1.6 | ≈1.6 | 0.1 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$5.1M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 6, 2026 | $1.10 | $0.39 | 179.5% |
| 31 Mart 2026 | $2.07 | $1.21 | 71.5% | |
| 31 Aralık 2025 | $-1.24 | $-0.91 | -37.0% | |
| 30 Eylül 2025 | $-0.53 | $-0.57 | 6.6% | |
| 30 Haziran 2025 | $-0.89 | $-0.47 | -88.5% | |
| 31 Mart 2025 | $0.92 | $0.81 | 13.8% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.70B | $9.18B | $5.86B | $3.96B | $1.84B | $463M | |
| SG&A Expense | $2.05B | $1.76B | $1.43B | $1.26B | $265M | $167M | |
| Operating Income | $-396M | $57M | $-236M | $-590M | $-544M | $-402M | |
| Interest Expense | · | · | $25M | $23M | $5M | $4M | |
| Other Non-op | $-23M | $-105.0K | $-7M | $2M | $-1M | · | |
| Pretax Income | $-437M | $33M | $-267M | $-610M | $-571M | $-406M | |
| Income Tax | $6M | $7M | $3M | $-523.0K | $846.0K | $1M | |
| Net Income | $-443M | $25M | $-271M | $-606M | $-573M | $-407M | |
| EPS (Basic) | $-1.69 | $0.11 | $-1.22 | $-2.85 | $-3.20 | $-14.16 | |
| EPS (Diluted) | $-1.69 | $0.10 | $-1.22 | $-2.85 | $-3.20 | $-14.16 | |
| Shares (Basic) | 262,388,000 | 240,386,000 | 221,655,000 | 212,475,000 | 178,967,056 | 29,263,424 | |
| Shares (Diluted) | 262,388,000 | 265,853,000 | 221,655,000 | 212,475,000 | 178,967,056 | 29,263,424 | |
| EBITDA | $-367M | $89M | $-205M | · | $-530M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.77B | $1.53B | $1.87B | $1.56B | $1.10B | $826M | |
| Short-term Investments | · | $624M | $690M | · | · | · | |
| Receivables | $363M | · | · | · | · | · | |
| Other Current Assets | $24M | $21M | $7M | $6M | $4M | · | |
| Current Assets | $4.61B | $2.85B | $3.06B | $4.12B | $2.31B | $1.87B | |
| PP&E (Net) | $88M | $67M | $62M | $60M | $47M | $36M | |
| PP&E (Gross) | $230M | $181M | $150M | $117M | $89M | $63M | |
| Accum. Depreciation | $142M | $114M | $88M | $57M | $42M | $27M | |
| Other Non-current Assets | $120M | $82M | $83M | $95M | $97M | $13M | |
| Total Assets | $6.33B | $4.84B | $3.60B | $4.53B | $3.32B | $2.27B | |
| Accounts Payable | $507M | $432M | $273M | $298M | $235M | $138M | |
| Current Liabilities | $4.86B | $3.46B | $2.43B | $3.26B | $1.85B | $1.67B | |
| Capital Leases | $52M | $61M | $67M | $72M | $77M | · | |
| Other Non-current Liabilities | $52M | $61M | $68M | $72M | $77M | $0 | |
| Total Liabilities | $5.34B | $3.82B | $2.80B | $3.63B | $1.93B | $1.82B | |
| Total Debt | $430M | $300M | $299M | · | $0 | · | |
| Common Stock | · | · | · | · | · | $2.0K | |
| Paid-in Capital | $4.26B | $3.87B | $3.68B | $3.51B | $3.39B | $133M | |
| Retained Earnings | $-3.29B | $-2.85B | $-2.88B | $-2.61B | $-2.00B | $-1.43B | |
| Treasury Stock | $3M | $3M | $3M | $3M | $3M | $3M | |
| AOCI | $18M | $-2M | $1M | $-10M | $-4M | $879.0K | |
| Stockholders' Equity | $978M | $1.01B | $804M | $890M | $1.39B | $-1.30B | |
| Liabilities + Equity | $6.33B | $4.84B | $3.60B | $4.53B | $3.32B | $2.27B |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $29M | $32M | $31M | $15M | $15M | $11M | |
| Stock-based Comp | $88M | $110M | $160M | $112M | $86M | $36M | |
| Deferred Tax | $2M | $-2M | $58.0K | $-165.0K | $-101.0K | $-67.0K | |
| Other Non-cash | $1.42B | $813M | $-192M | · | $290M | · | |
| Operating Cash Flow | $1.09B | $978M | $-272M | $380M | $-182M | $223M | |
| CapEx | $36M | $28M | $26M | $29M | $26M | $14M | |
| Investing Cash Flow | $-241M | $-1.39B | $577M | $-227M | $-775M | $-345M | |
| Debt Issued | $410M | $0 | $0 | $305M | $0 | $147M | |
| Net Debt Issued | $410M | $0 | $0 | · | · | · | |
| Stock Repurchased | · | · | · | · | $0 | $0 | |
| Net Stock Activity | · | · | · | · | $0 | · | |
| Financing Cash Flow | $399M | $68M | $6M | $301M | $1.24B | $612M | |
| Net Change in Cash | $1.25B | $-341M | $311M | $455M | $282M | $490M | |
| Taxes Paid | $18M | $674.0K | $2M | $2M | $697.0K | $2M | |
| Free Cash Flow | $1.06B | $950M | $-298M | · | $-208M | · | |
| Levered FCF | · | · | $-323M | · | $-212M | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -3.4% | 0.62% | -4.0% | · | -29.6% | · | |
| Net Margin | -3.8% | 0.28% | -4.6% | · | -31.1% | · | |
| Pretax Margin | -3.7% | 0.36% | -4.6% | · | -31.0% | · | |
| EBITDA Margin | -3.1% | 0.97% | -3.5% | · | -28.8% | · | |
| ROA | -7.9% | 0.60% | -6.7% | · | -20.5% | · | |
| ROE | -44.5% | 2.8% | -32.0% | · | -36.7% | · | |
| ROIC | -28.5% | 3.4% | -21.6% | · | -39.3% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.8 | 1.3 | · | 1.2 | · | |
| Quick Ratio | 0.6 | 0.6 | 0.8 | · | 0.6 | · | |
| Debt / Equity | 0.4 | 0.3 | 0.4 | · | 0.0 | · | |
| LT Debt / Equity | 0.4 | 0.3 | 0.4 | · | 0.0 | · | |
| Interest Coverage | · | · | -9.6 | · | -115.4 | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.1 | 2.2 | 1.4 | · | 0.7 | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue / Share | $44.60 | $34.52 | $26.45 | · | $10.27 | · | |
| Cash Flow / Share | $4.17 | $3.68 | $-1.23 | · | $-1.02 | · | |
| EPS (TTM) | $-1.69 | $0.10 | $-1.22 | $-2.85 | $-3.20 | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | 27.5% | 56.5% | 47.9% | 115.6% | 297.3% | · | |
| Revenue CAGR 3Y | 43.5% | 70.9% | 133.1% | · | · | · | |
| Revenue CAGR 5Y | 90.8% | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.70B | $9.18B | $5.86B | $3.96B | $1.84B | · | |
| Net Income TTM | $-443M | $25M | $-271M | $-606M | $-573M | · | |
| P/E | -8.5 | 134.4 | -7.5 | -0.9 | -2.5 | · | |
| Earnings Yield | -11.8% | 0.74% | -13.3% | -115.9% | -40.8% | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.88B | $4.65B | $2.81B | $2.99B | $2.86B | $3.05B | $2.39B | $2.42B | $2.22B | $2.14B | $1.43B | $1.44B | $1.52B | $1.47B | $995M | $978M | |
| SG&A Expense | $691M | $706M | $511M | $522M | $534M | $483M | $466M | $460M | $435M | $394M | $364M | $326M | $337M | $399M | $1.02B | $79M | |
| Operating Income | $389M | $704M | $-334M | $-129M | $-230M | $297M | $-148M | $-48M | $68M | $186M | $-145M | $-58M | $-7M | $-25M | $-222M | $-192M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $6M | · | $6M | $6M | $6M | · | $6M | |
| Other Non-op | $-915.0K | $71.0K | $-20M | $-3M | $3M | $-3M | $68.0K | $2M | $-872.0K | $-1M | $1M | $-414.0K | $-2M | $-6M | $1M | $3M | |
| Pretax Income | $383M | $699M | $-353M | $-139M | $-234M | $288M | $-154M | $-52M | $61M | $178M | $-151M | $-65M | $-14M | $-38M | $-227M | $-195M | |
| Income Tax | $21M | $20M | $-247.0K | $-2M | $-5M | $13M | $-404.0K | $2M | $5M | $996.0K | $-806.0K | $915.0K | $1M | $2M | $-715.0K | $-2M | |
| Net Income | $362M | $679M | $-353M | $-137M | $-228M | $275M | $-154M | $-55M | $56M | $177M | $-150M | $-65M | $-16M | $-40M | $-226M | $-193M | |
| EPS (Basic) | $1.20 | $2.28 | $-1.37 | $-0.53 | $-0.89 | $1.10 | $-0.68 | $-0.22 | $0.24 | $0.77 | $-0.68 | $-0.29 | $-0.07 | $-0.18 | $-1.05 | $-0.91 | |
| EPS (Diluted) | $1.10 | $2.07 | $-1.19 | $-0.53 | $-0.89 | $0.92 | $-0.50 | $-0.22 | $0.20 | $0.62 | $-0.68 | $-0.29 | $-0.07 | $-0.18 | $-1.05 | $-0.91 | |
| Shares (Basic) | 302,220,000 | 298,184,000 | · | 259,273,000 | 255,531,000 | 251,279,000 | · | 243,106,000 | 238,672,000 | 231,443,000 | · | 223,099,000 | 219,400,000 | 216,913,000 | · | 212,822,733 | |
| Shares (Diluted) | 333,432,000 | 329,751,000 | · | 259,273,000 | 255,531,000 | 305,938,000 | · | 243,106,000 | 303,965,000 | 293,796,000 | · | 223,099,000 | 219,400,000 | 216,913,000 | · | 212,822,733 | |
| EBITDA | $389M | $711M | · | $-129M | $-230M | $304M | · | $-48M | $68M | $193M | · | $-58M | $-7M | $-20M | · | $-192M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.08B | $4.81B | $2.77B | $2.15B | $2.60B | $2.24B | $1.53B | $1.21B | $2.27B | $2.23B | $1.87B | $1.40B | $2.32B | $2.11B | $1.56B | $2.11B | |
| Receivables | $380M | $587M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $60M | $26M | $24M | $29M | $30M | $23M | $21M | $21M | $16M | $9M | · | $8M | $8M | $11M | · | $16M | |
| Current Assets | $9.37B | $7.78B | $4.61B | $3.76B | $4.31B | $3.77B | $2.85B | $2.37B | $3.36B | $3.50B | · | $2.99B | $4.19B | $4.13B | · | $3.93B | |
| PP&E (Net) | $101M | $94M | $88M | $83M | $78M | $72M | $67M | $67M | $64M | $61M | · | $62M | $63M | $64M | · | $56M | |
| PP&E (Gross) | · | · | $230M | · | · | · | $181M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $142M | · | · | · | $114M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $122M | $123M | $120M | $121M | $116M | $94M | $82M | $84M | $87M | $87M | · | $89M | $92M | $95M | · | $97M | |
| Total Assets | $11.23B | $9.29B | $6.33B | $5.75B | $6.38B | $5.84B | $4.84B | $4.48B | $5.01B | $4.42B | · | $3.35B | $4.56B | $4.48B | · | $4.31B | |
| Accounts Payable | $526M | $506M | $650M | $557M | $584M | $634M | $432M | $395M | $348M | $303M | · | $260M | $262M | $299M | · | $252M | |
| Current Liabilities | $8.69B | $7.14B | $4.86B | $3.98B | $4.87B | $4.15B | $3.46B | $2.95B | $3.50B | $3.02B | · | $2.06B | $3.24B | $3.18B | · | $2.85B | |
| Capital Leases | · | · | $52M | · | · | · | $61M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $50M | $51M | $52M | $56M | $57M | $59M | $61M | $64M | $65M | $66M | · | $69M | $70M | $71M | · | $74M | |
| Total Liabilities | $9.17B | $7.62B | $5.34B | $4.72B | $5.22B | $4.51B | $3.82B | $3.32B | $3.87B | $3.38B | · | $2.43B | $3.61B | $3.55B | · | $3.22B | |
| Total Debt | $432M | $431M | · | $686M | $300M | $300M | · | $299M | $299M | $299M | · | $299M | $298M | $298M | · | $298M | |
| Paid-in Capital | $4.32B | $4.28B | $4.26B | $3.95B | $3.95B | $3.90B | $3.87B | $3.84B | $3.79B | $3.74B | · | $3.65B | $3.62B | $3.58B | · | $3.48B | |
| Retained Earnings | $-2.25B | $-2.62B | $-3.29B | $-2.94B | $-2.80B | $-2.58B | $-2.85B | $-2.70B | $-2.64B | $-2.70B | · | $-2.73B | $-2.66B | $-2.65B | · | $-2.38B | |
| Treasury Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| AOCI | $-8M | $5M | $18M | $16M | $14M | $10M | $-2M | $26M | $-3M | $-3M | · | $-4M | $-7M | $-4M | · | $-14M | |
| Stockholders' Equity | $2.05B | $1.66B | $978M | $1.02B | $1.16B | $1.33B | $1.01B | $1.16B | $1.14B | $1.03B | · | $919M | $950M | $930M | · | $1.08B | |
| Liabilities + Equity | $11.23B | $9.29B | $6.33B | $5.75B | $6.38B | $5.84B | $4.84B | $4.48B | $5.01B | $4.42B | · | $3.35B | $4.56B | $4.48B | · | $4.31B |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $7M | $8M | $7M | $7M | $7M | $9M | $8M | $8M | $8M | $8M | $9M | $9M | $5M | $4M | $4M | |
| Stock-based Comp | $21M | $16M | $18M | $20M | $24M | $25M | $26M | $29M | $29M | $26M | $26M | $29M | $33M | $71M | $29M | $29M | |
| Deferred Tax | $-2M | $-6M | $3M | $-175.0K | $-36.0K | $36.0K | $-2M | $-119.0K | $130.0K | $-79.0K | $-37.0K | $69.0K | $209.0K | $-183.0K | $-171.0K | $2.0K | |
| Other Non-cash | · | $1.92B | · | · | · | $572M | · | · | · | $423M | · | · | · | $378M | · | · | |
| Operating Cash Flow | $2.09B | $2.62B | $672M | $-965M | $509M | $879M | $347M | $-500M | $497M | $634M | $297M | $-1.15B | $166M | $415M | $151M | $-548M | |
| CapEx | $12M | $9M | $9M | $9M | $9M | $9M | $7M | $8M | $8M | $6M | $6M | $6M | $6M | $7M | $7M | $10M | |
| Investing Cash Flow | $-2.83B | $-590M | $-49M | $150M | $-168M | $-174M | $-31M | $-578M | $-478M | $-301M | $172M | $225M | $44M | $136M | $-707M | $299M | |
| Debt Issued | · | · | $0 | · | · | · | $0 | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $13M | $-4M | $8M | $364M | $22M | $5M | $4M | $19M | $19M | $27M | $1M | $2M | $3M | $506.0K | $527.0K | $423.0K | |
| Net Change in Cash | $-729M | $2.03B | $631M | $-451M | $363M | $709M | $319M | $-1.06B | $38M | $361M | $470M | $-922M | $212M | $551M | $-555M | $-249M | |
| Taxes Paid | $1M | $44.0K | $19.0K | $2M | $15M | $0 | $38.0K | $552.0K | · | · | $1M | $600.0K | · | · | $233.0K | $555.0K | |
| Free Cash Flow | · | $2.61B | · | · | · | $870M | · | · | · | $628M | · | · | · | $407M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $623M | · | · | · | $401M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 8.0% | 15.2% | · | -4.3% | -8.1% | 9.8% | · | -2.0% | 3.1% | 8.7% | · | -4.0% | -0.43% | -1.7% | · | -19.7% | |
| Net Margin | 7.4% | 14.6% | · | -4.6% | -8.0% | 9.0% | · | -2.2% | 2.5% | 8.3% | · | -4.5% | -1.0% | -2.7% | · | -19.7% | |
| Pretax Margin | 7.8% | 15.0% | · | -4.7% | -8.2% | 9.5% | · | -2.2% | 2.8% | 8.3% | · | -4.5% | -0.94% | -2.6% | · | -20.0% | |
| EBITDA Margin | 8.0% | 15.3% | · | -4.3% | -8.1% | 10.0% | · | -2.0% | 3.1% | 9.0% | · | -4.0% | -0.43% | -1.4% | · | -19.7% | |
| ROA | 4.1% | 9.0% | · | -2.7% | -4.0% | 5.4% | · | -1.4% | 1.2% | 4.0% | · | -1.7% | -0.33% | -0.90% | · | -5.2% | |
| ROE | 22.5% | 45.3% | · | -12.6% | -19.9% | 23.3% | · | -5.2% | 5.4% | 18.1% | · | -6.5% | -1.4% | -3.5% | · | -14.6% | |
| ROIC | 14.8% | 32.7% | · | -7.5% | -15.5% | 17.4% | · | -3.4% | 4.4% | 13.9% | · | -4.9% | -0.57% | -2.2% | · | -13.8% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.1 | · | 0.9 | 0.9 | 0.9 | · | 0.8 | 1.0 | 1.2 | · | 1.5 | 1.3 | 1.3 | · | 1.4 | |
| Quick Ratio | 0.5 | 0.8 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | |
| Debt / Equity | 0.2 | 0.3 | · | 0.7 | 0.3 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| LT Debt / Equity | 0.2 | 0.3 | · | 0.7 | 0.3 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 31.4 | · | -9.5 | -1.1 | -4.1 | · | -31.4 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 25.7 | 15.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $14.64 | $14.09 | · | $11.52 | $11.21 | $9.96 | · | $9.97 | $7.30 | $7.29 | · | $6.45 | $6.93 | $6.78 | · | $4.60 | |
| Cash Flow / Share | · | $7.94 | · | · | · | $2.87 | · | · | · | $2.16 | · | · | · | $1.91 | · | · | |
| EPS (TTM) | $1.45 | $-0.54 | · | $-1.00 | $-0.69 | $0.40 | · | $-0.08 | $-0.15 | $-0.42 | · | $-1.59 | $-2.21 | $-2.67 | · | $-2.63 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $15.32B | $13.30B | · | $11.29B | $10.73B | $10.08B | · | $8.22B | $7.23B | $6.54B | · | $5.43B | $4.96B | $4.46B | · | $3.46B | |
| Net Income TTM | $551M | $-39M | · | $-244M | $-161M | $123M | · | $29M | $18M | $-54M | · | $-347M | $-474M | $-571M | · | $-579M | |
| P/E | 19.7 | -21.2 | · | -18.9 | -31.1 | 32.8 | · | -265.1 | -105.5 | -35.4 | · | -3.5 | -3.6 | -2.4 | · | -1.9 | |
| Earnings Yield | 5.1% | -4.7% | · | -5.3% | -3.2% | 3.0% | · | -0.38% | -0.95% | -2.8% | · | -28.5% | -27.4% | -40.8% | · | -52.7% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $11.70B | $9.18B | $5.86B | $3.96B | $1.84B |
| Faaliyet Kâr Marjı % | -3.4% | 0.62% | -4.0% | · | -29.6% |
| Net Gelir | $-443M | $25M | $-271M | $-606M | $-573M |
| Seyreltilmiş Hisse Başı Kâr | $-1.69 | $0.10 | $-1.22 | $-2.85 | $-3.20 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.4 | 0.3 | 0.4 | · | 0.0 |
| Cari Oran | 0.9 | 0.8 | 1.3 | · | 1.2 |
| Cari Oran | 0.6 | 0.6 | 0.8 | · | 0.6 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $1.06B | $950M | $-298M | · | $-208M |
Kurumsal Sahipler (13F) 459 dosya · $6.2B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 125 (+51 önceki Ç'ye göre) | 46 (-18 önceki Ç'ye göre) | 147 (+22 önceki Ç'ye göre) | 115 (+3 önceki Ç'ye göre) | +22.8M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $587.153.449 | 20.587.428 | 9,50% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $360.595.957 | 12.643.617 | 5,84% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $314.559.172 | 11.029.424 | 5,09% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $301.725.543 | 10.579.437 | 4,88% | Hisse senetleri |
| VANGUARD GROUP INC | $297.476.962 | 20.701.250 | 4,82% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $258.255.502 | 9.055.242 | 4,18% | Hisse senetleri |
| JANE STREET GROUP, LLC | $181.530.912 | 6.365.039 | 2,94% | Hisse senetleri |
| Thrive Capital Management, LLC | $180.919.957 | 6.343.617 | 2,93% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $165.994.311 | 5.819.186 | 2,69% | Hisse senetleri |
| STATE STREET CORP | $165.454.531 | 5.801.351 | 2,68% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $162.917.648 | 5.712.400 | 2,64% | Alım opsiyonu |
| FMR LLC | $142.557.861 | 4.998.523 | 2,31% | Hisse senetleri |
| CITADEL ADVISORS LLC | $120.626.823 | 4.229.552 | 1,95% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $115.097.850 | 4.035.689 | 1,86% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $101.885.043 | 3.571.731 | 1,65% | Hisse senetleri |
| BIT Capital GmbH | $97.480.134 | 3.417.957 | 1,58% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $93.673.940 | 3.284.500 | 1,52% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $86.282.012 | 3.025.316 | 1,40% | Hisse senetleri |
| GLYNN CAPITAL MANAGEMENT LLC | $73.462.615 | 2.575.828 | 1,19% | Hisse senetleri |
| CITADEL ADVISORS LLC | $72.469.320 | 2.541.000 | 1,17% | Alım opsiyonu |
| GOLDMAN SACHS GROUP INC | $65.298.165 | 2.289.557 | 1,06% | Hisse senetleri |
| NORTHERN TRUST CORP | $63.063.680 | 2.211.209 | 1,02% | Hisse senetleri |
| WOLVERINE ASSET MANAGEMENT LLC | $61.825.656 | 2.167.800 | 1,00% | Satım opsiyonu |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $60.458.493 | 2.119.863 | 0,98% | Hisse senetleri |
| MORGAN STANLEY | $60.299.272 | 2.114.280 | 0,98% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $55.351.616 | 1.940.800 | 0,90% | Satım opsiyonu |
| JANE STREET GROUP, LLC | $53.968.396 | 1.892.300 | 0,87% | Alım opsiyonu |
| Nuveen, LLC | $50.501.648 | 1.770.745 | 0,82% | Hisse senetleri |
| BlackBarn Capital Partners LP | $49.910.000 | 1.750.000 | 0,81% | Satım opsiyonu |
| BNP PARIBAS FINANCIAL MARKETS | $48.660.710 | 1.706.196 | 0,79% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $45.996.029 | 1.612.764 | 0,74% | Hisse senetleri |
| CITADEL ADVISORS LLC | $44.459.828 | 1.558.900 | 0,72% | Satım opsiyonu |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $41.354.000 | 1.450.000 | 0,67% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $37.594.294 | 1.318.173 | 0,61% | Hisse senetleri |
| Assenagon Asset Management S.A. | $35.592.732 | 1.247.992 | 0,58% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $35.534.136 | 2.472.800 | 0,58% | Hisse senetleri |
| UBS Group AG | $34.596.357 | 1.213.056 | 0,56% | Hisse senetleri |
| JANE STREET GROUP, LLC | $33.796.200 | 1.185.000 | 0,55% | Satım opsiyonu |
| GROUP ONE TRADING LLC | $32.744.154 | 1.148.112 | 0,53% | Hisse senetleri |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $31.200.652 | 1.093.992 | 0,51% | Hisse senetleri |
| Qube Research & Technologies Ltd | $30.913.940 | 1.083.939 | 0,50% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $29.055.948 | 1.018.792 | 0,47% | Hisse senetleri |
| GILDER GAGNON HOWE & CO LLC | $28.576.515 | 1.001.982 | 0,46% | Hisse senetleri |
| JPMORGAN CHASE & CO | $26.387.407 | 885.558 | 0,43% | Hisse senetleri |
| FEDERATED HERMES, INC. | $26.096.200 | 915.014 | 0,42% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $23.408.907 | 820.789 | 0,38% | Hisse senetleri |
| Walleye Capital LLC | $23.243.058 | 814.974 | 0,38% | Hisse senetleri |
| Point72 Asset Management, L.P. | $22.809.212 | 799.762 | 0,37% | Hisse senetleri |
| Walleye Trading LLC | $22.744.700 | 797.500 | 0,37% | Alım opsiyonu |
| Bank of New York Mellon Corp | $22.032.138 | 772.515 | 0,36% | Hisse senetleri |
Aktivistler ve %5+ sahipler 2 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Claremount TW, L.P., Claremount V Associates, L.P., Claremount VI Associates, L.P., Claremount VII Associates, L.P., Joshua Kushner, Thrive Capital Partners II, L.P., Thrive Capital Partners III, L.P., Thrive Capital Partners V, L.P., Thrive Capital Partners VI Growth, L.P., Thrive Capital Partners VII Growth, L.P., Thrive Partners II GP, LLC, Thrive Partners III GP, LLC, Thrive Partners V GP, LLC, Thrive Partners VI GP, LLC, Thrive Partners VII GP, LLC, Thrive Partners VII Growth GP, LLC | 18 Eylül 2026 | 12,10% | Değişiklik | · | SEC |
| Thrive Capital Partners II, L.P. (2), Thrive Partners II GP, LLC (2), Thrive Capital Partners III, L.P. (2), Claremount TW, L.P. (2), Thrive Partners III GP, LLC (2), Thrive Capital Partners V, L.P. (2), Claremount V Associates, L.P. (2), Thrive Partners V GP, LLC (2), Thrive Capital Partners VI Growth, L.P. (2), Claremount VI Associates, L.P. (2), Thrive Partners VI GP, LLC (2), Thrive Capital Partners VII Growth, L.P. (2), Thrive Partners VII Growth GP, LLC (2), Claremount VII Associates, L.P. (2), Thrive Partners VII GP, LLC (2), Joshua Kushner (2) ×4 başvurular | 13 Kasım 2024 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 23 içeriden öğrenenler · 12 yöneticiler · 12 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Mark T Bertolini | Chief Executive Officer | 30 Haziran 2026 S | 7.751.570 | 1 | 8 | $-58.759.399 |
| Richard Scott Blackley | Chief Financial Officer | 03 Eylül 2026 S | 1.046.108 | 0 | 9 | $-7.941.907 |
| Janet Liang | President, Oscar Insurance | 03 Eylül 2026 S | 248.697 | 0 | 5 | $-821.072 |
| Steven Wolin | Chief Operating Officer | 01 Aralık 2024 M | 102.598 | 0 | 0 | $0 |
| Meghan V. Joyce | Chief Operating Officer | 01 Mart 2022 M | 43.070 | 0 | 0 | $0 |
| Joshua Kushner | Co-Founder and Vice Chairman | 18 Eylül 2026 J | 0 | 0 | 0 | $0 |
| Victoria Baltrus | Chief Accounting Officer | 03 Eylül 2026 S | 213.631 | 0 | 5 | $-194.480 |
| Adam Mcananey | Chief Legal Officer | 03 Eylül 2026 S | 209.004 | 0 | 5 | $-783.513 |
| Alessandrea C. Quane | EVP, Chief Insurance Officer | 05 Aralık 2024 M | 430.216 | 0 | 0 | $0 |
| Ranmali Bopitiya | EVP & Chief Legal Officer | 01 Aralık 2024 M | 241.488 | 0 | 0 | $0 |
| Dennis Weaver | Chief Clinical Officer | 01 Aralık 2022 M | 27.110 | 0 | 0 | $0 |
| Joel Klein | Chief Policy & Strat. Officer | 18 Ağustos 2021 M | 17 | 0 | 0 | $0 |
| Vanessa Ames Wittman | Yönetim kurulu üyesi | 18 Eylül 2026 S | 112.121 | 0 | 1 | $-806.000 |
| Mario Schlosser | Yönetim kurulu üyesi | 03 Eylül 2026 S | 449.444 | 0 | 29 | $-68.790.950 |
| William Gassen | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 82.840 | 0 | 0 | $0 |
| David Plouffe | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 137.121 | 0 | 0 | $0 |
| Sid Sankaran | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 22.609 | 0 | 0 | $0 |
| Laura W Lang | Yönetim kurulu üyesi | 04 Haziran 2026 A | 82.840 | 0 | 0 | $0 |
| Jeffery H Boyd | Yönetim kurulu üyesi | 09 Nisan 2026 A | 705.673 | 0 | 0 | $0 |
| Elbert O. Robinson Jr. | Yönetim kurulu üyesi | 12 Mayıs 2025 S | 64.512 | 0 | 0 | $0 |
| Jr Charles E Phillips | Yönetim kurulu üyesi | 14 Ekim 2022 A | 85.787 | 0 | 0 | $0 |
| Teri List-Stoll | Yönetim kurulu üyesi | 05 Mart 2021 A | 50.000 | 0 | 0 | $0 |
| Ari Fischel | · | 05 Mart 2021 A | 0 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 46 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| ABLS · Abacus FCF ETF Trust | 5,83% | 867 NS | 31 Temmuz 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,95% | 188.213 SH | 02 Ekim 2026 | Günlük |
| RNIN · EA Series Trust | 1,20% | 70.047 NS | 31 Temmuz 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,74% | 307.696 NS | 31 Temmuz 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,60% | 69.666 NS | 31 Temmuz 2026 | N-PORT |
| IWO · iShares Trust | 0,52% | 2.269.828 SH | 11 Eylül 2026 | Günlük |
| JSMD · Janus Detroit Street Trust | 0,51% | 171.181 NS | 31 Temmuz 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,40% | 258.034 SH | 19 Ağustos 2026 | Günlük |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,36% | 48.469 SH | 02 Ekim 2026 | Günlük |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,35% | 152.933 NS | 31 Temmuz 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,31% | 8.798 NS | 31 Temmuz 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,27% | 61.099 NS | 31 Temmuz 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,27% | 19.102 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,26% | 6.175.602 SH | 11 Eylül 2026 | Günlük |
| FBUF · Fidelity Greenwood Street Trust | 0,25% | 1.889 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,24% | 71.367 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,24% | 115.406 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,21% | 1.387.125 SH | 19 Ağustos 2026 | Günlük |
| FHEQ · Fidelity Greenwood Street Trust | 0,21% | 61.010 NS | 31 Temmuz 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 3.171.535 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,16% | 805.292 NS | 31 Temmuz 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 145.781 SH | 02 Ekim 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 27.872 NS | 31 Temmuz 2026 | N-PORT |
| ESML · iShares Trust | 0,11% | 96.895 SH | 11 Eylül 2026 | Günlük |
| FNCL · FIDELITY COVINGTON TRUST | 0,08% | 61.975 NS | 31 Temmuz 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,08% | 5.488.922 SH | 19 Ağustos 2026 | Günlük |
| VFH · VANGUARD WORLD FUND | 0,08% | 384.466 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,07% | 14.630 SH | 11 Eylül 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,07% | 2.534.194 SH | 19 Ağustos 2026 | Günlük |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 12.495 SH | 02 Ekim 2026 | Günlük |
| DFSU · Dimensional ETF Trust | 0,03% | 20.892 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,02% | 21.472 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 286.808 NS | 31 Temmuz 2026 | N-PORT |
| TILT · FlexShares Trust | 0,02% | 12.166 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,01% | 50.403 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 64.590 SH | 11 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 7.601.113 SH | 19 Ağustos 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 194.738 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 19.808 SH | 19 Ağustos 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,01% | 66.708 NS | 31 Temmuz 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,01% | 53.203 SH | 19 Ağustos 2026 | Günlük |
| ITOT · iShares Trust | 0,01% | 287.602 SH | 11 Eylül 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,00% | 472 NS | 31 Temmuz 2026 | N-PORT |
| IAK · iShares Trust | · | 117.671 SH | 11 Eylül 2026 | Günlük |
| ISCB · iShares Trust | · | 10.063 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 286.871 SH | 11 Eylül 2026 | Günlük |
OSCR Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
12 Aylık Fiyat Hedefi
10 analist · 2026-10-03Ortalama hedef $35.40 +14,4%
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| OSCR | · | -8.5 | 27.5% | -3.8% | -44.5% | · |
| AFL | $57.20B | 16.2 | -9.3% | 21.2% | 12.9% | · |
| PRU | · | · | · | · | · | · |
| PFG | $19.18B | 16.8 | -3.1% | 7.6% | 10.3% | · |
| UNM | · | · | · | · | · | · |
| GL | $12.90B | 9.9 | 3.7% | 19.4% | 20.4% | · |
| PRI | $8.22B | 11.3 | 6.6% | 22.8% | 31.9% | · |
| LNC | $8.46B | 7.6 | -1.2% | 6.5% | 12.3% | · |
| CNO | $4.01B | 18.5 | 0.85% | 5.1% | 8.9% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.